GlassScriptPhysician profile
Meredith Lanham Mueller
NPI 1699141598
$5,785.69
in general payments reported to CMS, 2019-2025
23 companies · $579 in 2025
The $579 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $654 · 2021: $910 · 2022: $973 · 2023: $883 · 2024: $1,003 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.45 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $664.16 | 2020-2023 | |
| Aerie Pharmaceuticals, INC. | $581.10 | 2019-2021 | |
| Allergan, INC. | $556.40 | 2019-2022 | |
| Abbvie INC. | $545.74 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $531.77 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Alcon Vision LLC | $427.53 | 2020-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $361.10 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $341.33 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $308.14 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $295.59 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $288.10 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $241.89 | 2020-2023 | Tepezza |
| Shire North American Group INC | $170.03 | 2019 | |
| Amgen INC. | $89.66 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $79.05 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $77.45 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $51.90 | 2019-2021 | |
| Ivantis, INC | $45.43 | 2020 | |
| Harrow Eye, LLC | $43.78 | 2024 | Vevye |
| Sight Sciences, INC. | $28.67 | 2023-2024 | Omni Surgical System, Tearcare System |
| Kala Pharmaceuticals, INC. | $23.21 | 2021 | |
| Rayner Intraocular Lenses Limited | $19.86 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.